# A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks

> **NCT07009262** · — · COMPLETED · sponsor: **KalVista Pharmaceuticals, Ltd.** · enrollment: 88 (actual)

## Conditions studied

- Hereditary Angioedema

## Interventions

- **OTHER:** Inapplicable

## Key facts

- **NCT ID:** NCT07009262
- **Lead sponsor:** KalVista Pharmaceuticals, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-04-21
- **Primary completion:** 2025-11-25
- **Final completion:** 2025-11-25
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2026-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07009262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07009262, "A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07009262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*